Filing summary
Company identity discrepancy: The supplied filing is for Synta Pharmaceuticals Corp., not Madrigal Pharmaceuticals, Inc. Verify the issuer and filing before relying on this summary.
Business context and reporting period
This unaudited Form 10-Q covers the quarter and six months ended June 30, 2015. Synta was a clinical-stage oncology biopharmaceutical company with no product revenue. Its programs included ganetespib, the HDC candidate STA-12-8666, and elesclomol.
Financial results and liquidity
| Metric | Q2 2015 / June 30, 2015 | Comparable period / prior year-end |
|---|---|---|
| Revenue | $0 | $0 in Q2 2014 |
| Research and development expense | $16.4 million for Q2; $32.6 million for six months | $18.8 million and $36.3 million, respectively, in 2014 |
| General and administrative expense | $3.1 million for Q2; $7.3 million for six months | $2.9 million and $8.3 million, respectively, in 2014 |
| Net loss | $19.8 million for Q2; $40.5 million for six months | $22.3 million and $45.8 million, respectively, in 2014 |
| Basic and diluted loss per share | $0.15 for Q2; $0.34 for six months | $0.24 and $0.51, respectively, in 2014 |
| Cash, cash equivalents and marketable securities | $98.3 million | $97.7 million at December 31, 2014 |
| Working capital | $68.0 million | $81.7 million at June 30, 2014 |
| Term loans | $9.2 million principal outstanding; $9.2 million classified current and $0.01 million long term | — |
For the six months, operating cash use was $36.5 million, investing cash use was $14.7 million, and financing provided $37.2 million. Financing included approximately $41.8 million net proceeds from an April public offering; the company also paid $4.6 million of term-loan principal. Cash and cash equivalents alone were $32.0 million at June 30. Profit margins are not meaningful because the company reported no revenue and operating losses.
Material changes versus comparable periods
- Six-month net loss narrowed by about $5.3 million year over year, while R&D expense declined $3.8 million and G&A declined $1.0 million. Lower ganetespib and early-stage program spending and reduced prior-year executive separation costs contributed to lower expenses; spending on STA-12-8666 increased.
- Q2 R&D fell $2.4 million year over year, mainly reflecting lower ganetespib and early-stage program costs, partly offset by $2.1 million of STA-12-8666 spending. Q2 G&A rose $0.2 million.
- Interest expense declined to $0.7 million for the first half from $1.2 million, primarily due to scheduled loan repayments.
- The April 2015 offering sold 25.3 million shares at $1.75 per share for approximately $41.8 million net proceeds. Common shares outstanding were 134.1 million at June 30, versus 109.1 million at December 31, 2014.
Outlook, commentary and risks
- Management estimated that the $98.3 million of cash, cash equivalents and marketable securities would fund operations at least through the first half of 2016, assuming no new partnership funding, equity financing, or additional ATM sales. The filing warns that funding may be needed earlier and that this estimate depends on development costs and clinical outcomes.
- Management anticipated that R&D spending could increase as GALAXY-2 and I-SPY 2 advance and STA-12-8666 moves through preclinical development. The company targeted an IND submission for STA-12-8666 by Q1 2016 and expected to nominate another HDC candidate in the first half of 2016.
- GALAXY-2 was an ongoing Phase 3 ganetespib trial in second-line NSCLC. Management expected its first overall-survival interim analysis by the end of 2015, further analyses in 2016, and contemplated seeking regulatory approval in 2016 only if interim results were positive and subject to regulatory feedback. These were forward-looking expectations, not reported outcomes.
- Funding options included additional equity, debt, collaborations, or licensing. These may be unavailable or dilute shareholders, impose unfavorable terms, or require surrendering program rights. Approximately $27 million remained available under the ATM arrangement; management also planned to file a new shelf registration statement for up to $300 million.
- Term loans carried stated annual rates of 9.75% (GECC) and 13.35% (Oxford). GECC debt was secured by substantially all assets except intellectual property, with a springing IP security interest under specified covenant conditions; loan agreements included restrictive covenants. A $788,000 GECC exit fee was due with the final principal payment.
- Clinical development, regulatory approval, commercialization, and future financing were substantial uncertainties. The company had an accumulated deficit of $678.1 million and stated it might never achieve product revenue or profitability. No material legal proceedings or material changes to previously disclosed risk factors were reported.
Important facts for investors to verify
- Confirm that the intended filing is Synta Pharmaceuticals Corp.’s Q2 2015 10-Q, rather than a Madrigal Pharmaceuticals filing.
- Check subsequent GALAXY-2 results and whether the stated interim-analysis and potential regulatory timelines were achieved.
- Assess the cash runway against actual operating cash burn, trial spending, and any subsequent financing or partnership proceeds.
- Review the impact of the April share issuance, available ATM capacity, and any later equity issuance on dilution.
- Verify current status, repayment terms, covenants, and collateral arrangements for the GECC and Oxford loans.